1,2-Dichloroethane → 1-(2,2-Diphenylethyl)-3-[N-(1-(4-cyanobenzyl)-1H-imidazol-5-ylethyl)carbamoyl]piperidine

HRID 365451ノート

反応式

HRID 365451 の反応式
[C:1]1([CH:7]([C:18]2[CH:23]=[CH:22][CH:21]=[CH:20][CH:19]=2)[CH2:8][N:9]2[CH2:14][CH2:13][CH2:12][CH:11]([C:15](O)=[O:16])[CH2:10]2)[CH:6]=[CH:5][CH:4]=[CH:3][CH:2]=1.[C:24]([C:26]1[CH:40]=[CH:39][C:29]([CH2:30][N:31]2[C:35]([CH2:36][CH2:37][NH2:38])=[CH:34][N:33]=[CH:32]2)=[CH:28][CH:27]=1)#[N:25].C1C=CC2N(O)N=NC=2C=1.C(Cl)CCl.CCN(CC)CC>CN(C=O)C>[C:1]1([CH:7]([C:18]2[CH:23]=[CH:22][CH:21]=[CH:20][CH:19]=2)[CH2:8][N:9]2[CH2:14][CH2:13][CH2:12][CH:11]([C:15](=[O:16])[NH:38][CH2:37][CH2:36][C:35]3[N:31]([CH2:30][C:29]4[CH:39]=[CH:40][C:26]([C:24]#[N:25])=[CH:27][CH:28]=4)[CH:32]=[N:33][CH:34]=3)[CH2:10]2)[CH:2]=[CH:3][CH:4]=[CH:5][CH:6]=1

参加物

7

実験手順

1-(2,2-Diphenylethyl)-3-carboxy piperidine(472 mg, 1,52 mmol),3-(4-cyanobenzyl) histamine (456 mg, 1.52 mmol) (EXAMPLE 1, Step E) HOBT (216 mg, 1.60 mmol), EDC (307 mg, 1.60 mmol), and Et3N (637 uL, 4.57 mmol) were dissolved in DMF (10 mL) and was stirred overnight at ambient temperature. The solution was concentrated under reduced pressure and chromatographed (silica gel, 0.5-2% MeOH/CH2Cl2 with NH4OH) to give the title compound 1H NMR (CDCl3) δ 7.96 (br s, 1H), 7.60 d, 2H, J=8 Hz), 7.46 (s, 1H), 7.09-7.37 (m, 12H), 6,74 (s, 1H), 5.20 (s, 2H), 4.26 (t, 1H, J=8 Hz), 3.05-3.17 (m, 2H), 2.93-3.04 (m,1H), 2.78-2.91 (m,2H), 2.49-2,61 (m 1H), 22.40-2.47 (m, 1H), 2.15-2.30 (m, 2H), 1.95-2.14 (m, 2H), 1.86 (d, 1H, J=12 Hz), 1.29-1.55 (m, 3H). FAB MS 518 (M+1)

後処理

  1. concentrationThe solution was concentrated under reduced pressure
  2. customchromatographed (silica gel, 0.5-2% MeOH/CH2Cl2 with NH4OH)

出典と根拠

ORDレコード
ord-9e79f8b6d889493aba103174744f693c
出典データセット
uspto-grants-2000_10
特許番号
US06127366

反応ノート

読み込み中…